R.J.Argüello is a Molecular Immunology expert with a tenured position at CNRS. Primary inventor SCENITHTM; a patented method to functionally profile metabolism with single-cell resolution. After his PhD in human immunology, and postdoctoral research at CIML and UCSF (Pierre and Krummel labs), he shifted focus to metabolism and epigenetics in immune cells. Since obtaining tenure, he secured prestigious grants and publications. He received the "Diversity-Equity and Inclusion Paper of the Year Award (2021)" and was selected for ISAC's Emerging-Leadership M. Ingram Program. He co-founded GammaOmics, Personalised-Medicine technologies, is member of the NPO-Expedición Ciencia and a founding member of the European ImmunoMetabolism Network.

Dr Emily Edwards is a Senior Postdoctoral Fellow in the Department of Immunology and Pathology at Monash University in Melbourne, Australia. Emily completed her PhD studies at Cardiff University before relocating to Australia. She joined the QIMR Berghofer Medical Research Institute in Brisbane in 2011. Here, she studied the phenotypic and functional attributes of CMV-specific CD4+ T cells. In 2014, she was recruited to Prof Stuart Tangye’s Laboratory at the Garvan Institute in Sydney where she commenced her studies in to the molecular and cellular underpinnings of Primary Immunodeficiency (PID). Here, she primarily focused on identifying rare genetic defects that render patients susceptible to severe EBV-associated disease. During this time, she was part of the team who first described CD70-deficiency, and published insights into the mechanisms underlying disease in activated PI3Kδ disease, MAGT1-deficiency and CD27-deficiency. Emily was recruited to A/Prof Menno van Zelm’s laboratory at Monash University 2018, where she continues her research interest in identifying new genetic defects underlying immunodeficiency, autoimmunity and gastrointestinal disease in Predominantly Antibody Deficiency (PAD). Emily’s work focuses on identifying functional and genetic defects causing PAD. She is the 2022 recipient of the Grifols ASPIRE (Award for Scientific Progress in Immunodeficiency Research) Award which will enable her to develop and standardise functional testing protocols, and new bioinformatic analysis pipelines to facilitate this work. The ultimate aim of this program is advance genetic diagnosis of PAD, thereby increasing patient access to personalised medicine which is urgently needed to reduce the incidence of irreversible organ damage and early death. Additionally, she received an Allergy and Immunology Foundation of Australasia (AIFA) Primary Immunodeficiency Clinical Research Grant to fund her work examining the SARS-CoV-2-specific antibody levels and neutralization capacity of Australian Immunoglobulin product, and the retention of these capabilities in Primary Immunodeficiency patient plasma. The broader aim of this project is to examine the SARS-CoV-2-specific humoral response (antibody and memory B-cell) to COVID-19 vaccination in Primary Immunodeficiency.